Indegene Collaborates with Microsoft to Scale GenAI Adoption in Life Sciences Companies

Healthcare technology company Indegene has joined forces with Microsoft to leverage generative AI for the medical industry. The partnership aims to empower global life sciences companies to scale up the adoption of enterprise-grade generative AI (GenAI) services and drive faster innovation.

Indegene provides digitally enabled commercialization services for the life sciences sector, emerging biotech firms, and medical device firms.

Tarun Mathur, CTO of Indegene, says, "GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we're closely working with many of our clients to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage.”

"With a focus on the right use cases, a responsible and compliant approach to scaling up, and shared learnings, we put generative AI to work for our clients," adds Mathur.

Some of the key use cases that the collaboration focuses on include:

1. Content super app: Using Azure OpenAI Service, the modular content value chain simplifies content creation and tagging for life sciences companies, offering a comprehensive view of the content process.

2. Future-ready medical content value chain: From sourcing content from relevant literature articles to authoring core documents such as Clinical Study Reports (CSRs) and Protocols, Indegene's solutions accelerate authoring processes and help ensure compliance across clinical and regulatory domains

3. Data management and analytics for clinical trials: Using Microsoft Fabric, Indegene’s solutions enhance the process of data ingestion and refinement, facilitate effortless reporting, and guarantee governance.